Literature DB >> 19131427

A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.

Takeharu Yamanaka1, Fumihiro Tanaka, Seiki Hasegawa, Morihito Okada, Toshinori Soejima, Norihiko Kamikonya, Kazuya Fukuoka, Takashi Nakano.   

Abstract

A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131427     DOI: 10.1093/jjco/hyn145

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Early mesothelioma revisited.

Authors:  Seiki Hasegawa
Journal:  Int J Clin Oncol       Date:  2012-01-11       Impact factor: 3.402

Review 2.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

3.  Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.

Authors:  Valerie W Rusch; Dorothy Giroux
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis.

Authors:  Hidenori Matsuzaki; Megumi Maeda; Suni Lee; Yasumitsu Nishimura; Naoko Kumagai-Takei; Hiroaki Hayashi; Shoko Yamamoto; Tamayo Hatayama; Yoko Kojima; Rika Tabata; Takumi Kishimoto; Junichi Hiratsuka; Takemi Otsuki
Journal:  J Biomed Biotechnol       Date:  2012-02-06

Review 5.  Asbestos induces reduction of tumor immunity.

Authors:  Naoko Kumagai-Takei; Megumi Maeda; Ying Chen; Hidenori Matsuzaki; Suni Lee; Yasumitsu Nishimura; Junichi Hiratsuka; Takemi Otsuki
Journal:  Clin Dev Immunol       Date:  2011-10-04

Review 6.  Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.

Authors:  Seiki Hasegawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-03-19

Review 7.  Multimodality treatment of malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul Van Schil
Journal:  F1000Res       Date:  2018-10-22

8.  Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).

Authors:  Seiki Hasegawa; Morihito Okada; Fumihiro Tanaka; Takeharu Yamanaka; Toshinori Soejima; Norihiko Kamikonya; Tohru Tsujimura; Kazuya Fukuoka; Kohei Yokoi; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2015-11-17       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.